- Home
- BEATW vs NRDS Comparison
BEATW vs NRDS Comparison
Compare BEATW & NRDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- NRDS
- Stock Information
- Founded
- BEATW 2015
- NRDS 2009
- Country
- BEATW United States
- NRDS United States
- Employees
- BEATW 20
- NRDS N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- NRDS EDP Services
- Sector
- BEATW Technology
- NRDS Technology
- Exchange
- BEATW Nasdaq
- NRDS Nasdaq
- Market Cap
- BEATW N/A
- NRDS N/A
- IPO Year
- BEATW N/A
- NRDS 2021
- Fundamental
- Price
- BEATW $0.51
- NRDS $9.49
- Analyst Decision
- BEATW
- NRDS Buy
- Analyst Count
- BEATW 0
- NRDS 5
- Target Price
- BEATW N/A
- NRDS $17.00
- AVG Volume (30 Days)
- BEATW 4.7K
- NRDS 533.6K
- Earning Date
- BEATW 03-14-2025
- NRDS 04-24-2025
- Dividend Yield
- BEATW N/A
- NRDS N/A
- EPS Growth
- BEATW N/A
- NRDS N/A
- EPS
- BEATW N/A
- NRDS 0.38
- Revenue
- BEATW N/A
- NRDS $687,600,000.00
- Revenue This Year
- BEATW N/A
- NRDS $12.65
- Revenue Next Year
- BEATW N/A
- NRDS $8.37
- P/E Ratio
- BEATW N/A
- NRDS $24.95
- Revenue Growth
- BEATW N/A
- NRDS 14.71
- 52 Week Low
- BEATW $0.50
- NRDS $8.75
- 52 Week High
- BEATW $0.62
- NRDS $16.45
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- NRDS 43.41
- Support Level
- BEATW N/A
- NRDS $8.78
- Resistance Level
- BEATW N/A
- NRDS $9.62
- Average True Range (ATR)
- BEATW 0.00
- NRDS 0.34
- MACD
- BEATW 0.00
- NRDS 0.19
- Stochastic Oscillator
- BEATW 0.00
- NRDS 78.72
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.